LOAd732 / Lokon - LARVOL DELTA

Targeting soft-tissue sarcoma with tumor microenvironment gene engineering drives NK cell antitumoral responses and reduces factors that promote tumor progression (CIMT 2026) - "In conclusion, TME gene engineering vectors LOAd703 and LOAd732 induced antitumor NK cell activation both in vitro and in vivo. Based on these findings, LOAd703 and especially LOAd732 represent a promising novel therapeutic approach for STS."

Biomarker • IO biomarker • Tumor microenvironment • Cytomegalovirus Infection • Infectious Disease • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CCL2 • CD40LG • CXCL1 • GZMB • IFNG • IL2 • PD-1 • TGFB1

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. (PubMed, J Transl Med) - "LOAd732 is a novel immunostimulatory gene therapy based on an oncolytic adenovirus that expresses three transgenes, which are essential for mediating an anti-tumor immune response by activating DCs and stimulating T and NK cells even under imunosuppressive conditions commonly present in the TME. These qualities make LOAd732 an appealing new immunotherapy approach."

Gene therapy • IO biomarker • Journal • Gene Therapies • Immune Modulation • Infectious Disease • Melanoma • Oncology • Solid Tumor • CD40 • CD40LG • IL10 • IL2 • IL2RA • TGFB1